275 related articles for article (PubMed ID: 34996493)
21. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.
Rooper LM; Sharma R; Li QK; Illei PB; Westra WH
Am J Surg Pathol; 2017 Nov; 41(11):1561-1569. PubMed ID: 28719469
[TBL] [Abstract][Full Text] [Related]
22. Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung.
Izaki Y; Amatya VJ; Kambara T; Kushitani K; Miyata Y; Okada M; Takeshima Y
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067335
[TBL] [Abstract][Full Text] [Related]
23. Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A.
Dong Y; Li Y; Liu R; Li Y; Zhang H; Liu H; Chen J
Oncol Lett; 2020 Mar; 19(3):2223-2230. PubMed ID: 32194720
[TBL] [Abstract][Full Text] [Related]
24. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung.
Weissferdt A; Sepesi B; Ning J; Hermsen M; Ferrarotto R; Glisson B; Hanna E; Bell D
Curr Oncol Rep; 2023 Jan; 25(1):1-10. PubMed ID: 36422794
[TBL] [Abstract][Full Text] [Related]
25. Insulinoma-associated protein 1 is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens.
Viswanathan K; Siddiqui MT; Borczuk AC
J Am Soc Cytopathol; 2019; 8(6):299-308. PubMed ID: 31345782
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine differentiation in a large series of genetically-confirmed Ewing's sarcoma family tumor: Does it provide any diagnostic or prognostic information?
Machado I; Navarro S; López-Guerrero JA; Verdini L; Picci P; Giner F; Llombart-Bosch A
Pathol Res Pract; 2021 Mar; 219():153362. PubMed ID: 33610950
[TBL] [Abstract][Full Text] [Related]
27. INSM1 Expression in Breast Neoplasms with Neuroedocrine Features.
Metovic J; Castellano I; Marinelli E; Osella-Abate S; Sapino A; Cassoni P; Papotti M
Endocr Pathol; 2021 Dec; 32(4):452-460. PubMed ID: 34008122
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary Large Cell Neuroendocrine Carcinoma.
Yang L; Fan Y; Lu H
Pathol Oncol Res; 2022; 28():1610730. PubMed ID: 36304941
[TBL] [Abstract][Full Text] [Related]
29. The panel of syntaxin 1 and insulinoma-associated protein 1 outperforms classic neuroendocrine markers in pulmonary neuroendocrine neoplasms.
Zombori T; Turkevi-Nagy S; Sejben A; Juhász-Nagy G; Cserni G; Furák J; Tiszlavicz L; Krenács L; Kővári B
APMIS; 2021 Apr; 129(4):186-194. PubMed ID: 33417719
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
[No Abstract] [Full Text] [Related]
31. The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.
Lai BS; Tsang JY; Poon IK; Shao Y; Chan SK; Tam FK; Cheung SY; Shea KH; Tse GM
Oncologist; 2020 Sep; 25(9):e1318-e1329. PubMed ID: 32472950
[TBL] [Abstract][Full Text] [Related]
32. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
[TBL] [Abstract][Full Text] [Related]
33. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
[TBL] [Abstract][Full Text] [Related]
34. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
35. Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.
Kriegsmann K; Zgorzelski C; Kazdal D; Cremer M; Muley T; Winter H; Longuespée R; Kriegsmann J; Warth A; Kriegsmann M
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):237-242. PubMed ID: 30358615
[TBL] [Abstract][Full Text] [Related]
36. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.
Kuji S; Watanabe R; Sato Y; Iwata T; Hirashima Y; Takekuma M; Ito I; Abe M; Nagashio R; Omae K; Aoki D; Kameya T
Gynecol Oncol; 2017 Feb; 144(2):384-390. PubMed ID: 27908529
[TBL] [Abstract][Full Text] [Related]
37. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract.
Kim IE; Amin A; Wang LJ; Cheng L; Perrino CM
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):687-693. PubMed ID: 31876605
[TBL] [Abstract][Full Text] [Related]
38. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
39. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung.
Jiang SX; Kameya T; Shinada J; Yoshimura H
Mod Pathol; 1999 Apr; 12(4):362-9. PubMed ID: 10229500
[TBL] [Abstract][Full Text] [Related]
40. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.
Rodriguez EF; Fite JJ; Chowsilpa S; Maleki Z
Hum Pathol; 2019 Mar; 85():128-135. PubMed ID: 30502379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
